These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36964928)

  • 1. A novel brick for bispecific antibody construction.
    He Y; Ma H; Wang C; Ai Z; Wu Q; Chen H; Lu D
    Proteins; 2023 Aug; 91(8):1065-1076. PubMed ID: 36964928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
    Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
    J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity.
    Wang Y; Liu J; Pan H; Xing J; Wu X; Li Q; Wang Z
    J Vis Exp; 2018 Jul; (137):. PubMed ID: 30059039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.
    Wang L; Jiang H; Yin X; Liang T; Li G; Ding C; Yang M; Zhang L; Liu J; Xu Y
    Front Immunol; 2024; 15():1415834. PubMed ID: 38933272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.
    Gong S; Ren F; Wu D; Wu X; Wu C
    MAbs; 2017 Oct; 9(7):1118-1128. PubMed ID: 28692328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
    Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
    MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities and challenges of bi-specific antibodies.
    Segués A; Huang S; Sijts A; Berraondo P; Zaiss DM
    Int Rev Cell Mol Biol; 2022; 369():45-70. PubMed ID: 35777864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics.
    Villafuerte-Vega RC; Li HW; Slaney TR; Chennamsetty N; Chen G; Tao L; Ruotolo BT
    Anal Chem; 2023 May; 95(17):6962-6970. PubMed ID: 37067470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Dual-Fc Bispecific Antibody with Enhanced Fc Effector Function.
    Zhou F; Ben Y; Jiang H; Tan S; Mu G; Zha Z; Dong S; Huang S; Zhou Y; Jin Y; Chiu ML
    Biochemistry; 2024 Apr; 63(8):958-968. PubMed ID: 38426700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig
    Koga H; Kuroi H; Hirano R; Hirayama H; Nabuchi Y; Kuramochi T
    Antibodies (Basel); 2024 Jan; 13(1):. PubMed ID: 38247567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting.
    Gong S; Wu C
    Methods; 2019 Feb; 154():87-92. PubMed ID: 30081078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.